DeepTIL links invasive-margin lymphocyte density with colorectal cancer progression
Source check: Source checked. Not independent scientific confirmation.
Finding: DeepTIL used ResNet18 tumor and lymphocyte detectors to quantify immune-cell distributions in colorectal pathology slides. Lymphocyte density within 200 micrometres of the invasive margin remained associated with progression-free survival after adjustment in 180 Yonsei patients and 268 TCGA patients. This retrospective association does not establish clinical benefit; wide confidence intervals, model selection and the outcome-optimized cutpoint limit inference.
Technology: DeepTIL; ResNet18
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- DeepTIL ResNet18 tumor/TIL detectors quantify spatial TIL density; 200micrometre invasive-margin feature associates with progression-free survival in Yonsei180 and retrospective TCGA268.
- Test and result
- Retrospective prognostic analysis in Yonsei 180 and TCGA 268; adjusted associations replicated within the same study.
- Limitation / still unknown
- Prospective utility, independent-team replication and causal benefit were not established.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC9161341/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 21 Nov 2026. Review scope: Primary full paper Methods, Results and limitations plus Europe PMC bibliographic metadata;reviewed 2026-11-21..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.